SLC5A2 and chronic kidney disease: Over a mean follow-up period longer than two years, the subjects treated with SGLT2 inhibitors had a significantly lower risk of developing acute kidney injury (HR 0.49, 95% CI 0.39–0.63), CKD (HR 0.61, 95% CI 0.50–0.76), ESKF (HR 0.40, 95% CI 0.20–0.80), or heart failure (HR 0.72, 95% CI 0.56–0.92).